Form 4: Haemonetics Director Claire Pomeroy Reports Acquisition of Restricted Stock Units

Director Claire Pomeroy reported the acquisition of 2,207 restricted stock units (RSUs) of Haemonetics Corp on July 25, 2024.

Summary

• On July 25, 2024, Claire Pomeroy, a director of Haemonetics Corp, acquired 2,207 restricted stock units (RSUs).
• These RSUs were issued under the company's Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• The RSUs vest 100% on the first anniversary of the grant date.
• Each RSU represents the right to receive one share of Haemonetics Corp's common stock upon vesting.
• Following the transaction, Pomeroy directly owns 14,179 shares of Haemonetics Corp common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs by a director is generally a good sign, indicating confidence in the company's prospects. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs on the first anniversary of the grant date represents a future event that could impact the director's holdings.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of company stock, which is generally viewed positively by investors.

Stakeholder Impact

• The acquisition of RSUs by a director can positively influence shareholder sentiment.

Key Dates